Trial With LAVA-051 in Patients With Relapsed/Refractory CD1d (Cluster of Differentiation (CD)1d)-Positive CLL, MM, AML
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: phase 1 sequential dose escalation cohorts phase 2 parallel disease specific cohortsMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a phase 1/2a, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary anti-tumor activity of LAVA-051; a humanized gamma-delta bispecific T-cell engager (bsTCE) antibody, as monotherapy in subjects with relapsed or refract...
This is a phase 1/2a, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary anti-tumor activity of LAVA-051; a humanized gamma-delta bispecific T-cell engager (bsTCE) antibody, as monotherapy in subjects with relapsed or refractory CD1d-positive CLL, MM, or AML.
Tracking Information
- NCT #
- NCT04887259
- Collaborators
- Not Provided
- Investigators
- Study Chair: Benjamin Winograd, MD, PhD Lava Therapeutics
Get Well Soon